news agency

British Study Finds Moderna Vaccines Against COVID-19 Provide Greater Booster Impact

COVID-19 vaccines made by Pfizer and Moderna using mRNA technology provide the biggest boost to antibody levels when given 10 to 12 weeks after the second dose, according to a new British study.

The study “COV-Boost”Was quoted by British officials when they announced that they preferred to use Pfizer and Moderna in the country’s reinforcement campaign, but the data has only been made public now.

The study found that six of the seven boosters examined improved immunity after initial vaccination with the Pfizer-BioNTech vaccine, while all seven increased immunity when given after two doses of the AstraZeneca drug.

A third dose will be effective for many of the vaccines we have tested and in many different combinations.”, Explained the professor Saul Faust, an immunologist at the University of Southampton and leader of the trial.

The study found that a full dose or half dose of Pfizer or a full dose of Modern give a strong boost to both antibody and T-cell levels, regardless of whether the person initially received Pfizer O AstraZeneca.

The four most widely implemented vaccination regimens in the UK lead to essentially the same levels of immunity and are likely to be equally effective“Said the teacher Eleanor Riley, an immunologist at the University of Edinburgh. He also indicated that the data also supported a policy change on reinforcement.

These data support the decision of the JCVI (vaccine committee) earlier this week to advance the booster doses to three months after the second vaccination.“, he pointed.

When they were administered AstraZeneca, Novavax, Johnson & Johnson and Curevac as boosters, they increased antibody levels for any of the initial vaccines, albeit to a lesser degree, according to the study. However, although Valneva increased antibodies in people initially vaccinated with AstraZeneca, did not provide an impetus to Pfizer.

.

You may also like

Hot News

TRENDING NEWS

Subscribe

follow us

Immediate Access Pro